Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-992 pembrolizumab plus chemoradiotherapy in muscle-invasive bladder cancer
NL-OMON55121Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) comparing Pembrolizumab + chemoradiotherapy with Placebo + chemoradiotherapy (2 arms). Primary endpoint: Bladder intact event-free survival. Started Nov 2020; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55121.